Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
NEW YORK, Feb. 17, 2022 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its…
Comments Off on Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update